E. David Crawford

26.6k total citations · 7 hit papers
284 papers, 17.5k citations indexed

About

E. David Crawford is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, E. David Crawford has authored 284 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Pulmonary and Respiratory Medicine, 76 papers in Surgery and 55 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in E. David Crawford's work include Prostate Cancer Treatment and Research (158 papers), Prostate Cancer Diagnosis and Treatment (132 papers) and Hormonal and reproductive studies (55 papers). E. David Crawford is often cited by papers focused on Prostate Cancer Treatment and Research (158 papers), Prostate Cancer Diagnosis and Treatment (132 papers) and Hormonal and reproductive studies (55 papers). E. David Crawford collaborates with scholars based in United States, Canada and Belgium. E. David Crawford's co-authors include Catherine M. Tangen, Brent A. Blumenstein, Maha Hussain, Daniel P. Petrylak, Eric J. Small, Derek Raghavan, Robert C. Flanigan, Patrick A. Burch, Primo N. Lara and Mary Ellen Taplin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

E. David Crawford

276 papers receiving 16.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2004 2.9k citations Daniel P. Petrylak, Catherine M. Tangen et al. profile →
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2001 1.2k citations Brent A. Blumenstein, E. David Crawford et al. profile →
MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 891 citations Brent A. Blumenstein, James E. Montie et al. profile →
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

1998 685 citations Mario A. Eisenberger, Brent A. Blumenstein et al. profile →
Characterising the castration-resistant prostate cancer population: a systematic review

2011 635 citations E. David Crawford et al. profile →
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

2004 605 citations E. David Crawford et al. profile →
A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder

1991 469 citations Brent A. Blumenstein, E. David Crawford et al. profile →

Peers

Countries citing papers authored by E. David Crawford

Since Specialization

Citations

This map shows the geographic impact of E. David Crawford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. David Crawford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. David Crawford more than expected).

Fields of papers citing papers by E. David Crawford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. David Crawford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. David Crawford. The network helps show where E. David Crawford may publish in the future.

Co-authorship network of co-authors of E. David Crawford

This figure shows the co-authorship network connecting the top 25 collaborators of E. David Crawford. A scholar is included among the top collaborators of E. David Crawford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. David Crawford. E. David Crawford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of journal impact factor on publication times in orthopedic surgical journals 2025 ·Journal of Orthopaedic Reports ·E. David Crawford, (unknown), (unknown), (unknown), John Cyrus, (unknown)	0
2	Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi) 2021 ·European Urology Open Science ·Herjan J.T. Coelingh Bennink, (unknown), E. David Crawford, (unknown), Diederik M. Somford, Ton A. Roeleveld, (unknown), Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, (unknown), (unknown), Neal D. Shore, Fred Saad, Andrew V. Schally, F.M.J. Debruyne	14
3	ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC) 2017 ·Annals of Oncology ·Bertrand Tombal, Fred Saad, Maha Hussain, Cora N. Sternberg, Karim Fizazi, E. David Crawford, Karin Yamada, Christian Kappeler, Iris Kuss, Matthew R. Smith	1
4	Intermittent Androgen Deprivation with the GnRH Antagonist Degarelix in Men with Biochemical Relapse of Prostate Cancer 2015 ·E. David Crawford, Neal D. Shore, Celestia S. Higano, (unknown), (unknown)	2
5	The Role of the FSH System in the Development and Progression of Prostate Cancer 2014 ·E. David Crawford, Kyle O. Rove, Andrew V. Schally, Ferenc G. Rick, Norman L. Block, Thomas J.R. Beveridge, (unknown), Dennis C. Marshall	15
6	Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer 2012 ·Annals of Oncology ·Tanya B. Dorff, E. David Crawford	40
7	Role of Testosterone in Managing Advanced Prostate Cancer 2012 ·Urology ·Kyle O. Rove, F.M.J. Debruyne, Bob Djavan, Leonard G. Gomella, Hari K. Koul, M. Scott Lucia, Daniel P. Petrylak, Neal D. Shore, Nelson N. Stone, E. David Crawford	21
8	Androgen deprivation therapy: past, present and future 2012 ·British Journal of Urology ·Fritz H. Schröder, E. David Crawford, (unknown), Heather Payne, Thomas E. Keane	86
9	Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 2011 ·Cancer Prevention Research ·James R. Marshall, Catherine M. Tangen, Wael Sakr, David P. Wood, Donna L. Berry, Eric A. Klein, Scott M. Lippman, Howard L. Parnes, David S. Alberts, David F. Jarrard, W. Robert Lee, J. Michael Gaziano, E. David Crawford, Benjamin Ely, Michael Ray, Warren Davis, Lori M. Minasian, Ian M. Thompson	83
10	New and emerging agents for the treatment of castration-resistant prostate cancer 2011 ·Urologic Oncology Seminars and Original Investigations ·Celestia S. Higano, E. David Crawford	47
11	Targeted focal therapy for prostate cancer: a review 2009 ·Current Opinion in Urology ·(unknown), (unknown), E. David Crawford	29
12	Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer 2008 ·Urologic Oncology Seminars and Original Investigations ·Seth P. Lerner, Catherine M. Tangen, Heidi Sucharew, David P. Wood, E. David Crawford	73
13	Racial differences in serum prostate‐specific antigen (PSA) doubling time, histopathological variables and long‐term PSA recurrence between African‐American and white American men undergoing radical prostatectomy for clinically localized prostate cancer 2005 ·British Journal of Urology ·Ashutosh Tewari, Wolfgang Horninger, Ketan K. Badani, (unknown), Steven Coon, E. David Crawford, Eduard J. Gamito, John T. Wei, David A. Taub, James E. Montie, (unknown), George Divine, Georg Bartsch, Mani Menon	30
14	Surgical Management of Prostate Cancer: Optimizing Patient Selections and Clinical Outcome 2005 ·Surgical Oncology Clinics of North America ·Paul Maroni, E. David Crawford	1
15	The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial 2004 ·The Prostate ·Ali Ziada, Albaha Barqawi, L. Michael Glode, Marileila Varella‐Garcia, Frances Crighton, (unknown), Mark Rosenblum, Madeleine Kane, Lin Chen, E. David Crawford	141
16	The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer 2004 ·Urologic Oncology Seminars and Original Investigations ·Marileila Varella‐Garcia, Bülent Akduman, Patrapim Sunpaweravong, Michael V. Di Maria, E. David Crawford	37
17	Advancing Perspectives on Prostate Cancer: Multihormonal Influences in Pathogenesis 2001 ·PubMed ·Arthur T. Porter, Edgar Ben‐Josef, E. David Crawford, Seema V. Garde, Ilpo Huhtaniemi, (unknown)	3
18	Comparison of perspectives on prostate cancer: analyses of survey data 1997 ·Urology ·E. David Crawford, Charles L. Bennett, Nelson N. Stone, Sara J. Knight, Edward P. DeAntoni, Lisa K. Sharp, Marc B. Garnick, (unknown)	94
19	Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate 1995 ·American Journal of Clinical Oncology ·M. Ernest Marshall, Michael Wolf, E. David Crawford, Geoffrey R. Weiss, Frederick R. Ahmann, Fredrick J. Meyers, Brent A. Blumenstein, Mario A. Eisenberger, Albert Einstein	4
20	Intercostal nerve block with thoracoabdominal and flank incisions 1982 ·Urology ·E. David Crawford, Donald G. Skinner	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact